PROCHÁZKA, Vít, Robert PYTLÍK, Andrea JANÍKOVÁ, David BELADA, David ŠÁLEK, Tomáš PAPAJÍK, Vít CAMPR, Tomáš FÜRST, Jana FURSTOVA and Marek TRNĚNÝ. A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent. Plos one. San Francisco: Public Library Science, 2014, vol. 9, No 7, p. 1-10. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0102594.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
Authors PROCHÁZKA, Vít (203 Czech Republic), Robert PYTLÍK (203 Czech Republic), Andrea JANÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution), David BELADA (203 Czech Republic), David ŠÁLEK (203 Czech Republic, belonging to the institution), Tomáš PAPAJÍK (203 Czech Republic), Vít CAMPR (203 Czech Republic), Tomáš FÜRST (203 Czech Republic), Jana FURSTOVA (203 Czech Republic) and Marek TRNĚNÝ (203 Czech Republic).
Edition Plos one, San Francisco, Public Library Science, 2014, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.234
RIV identification code RIV/00216224:14110/14:00080009
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0102594
UT WoS 000341354800028
Keywords in English NON-HODGKINS-LYMPHOMA; ABSOLUTE LYMPHOCYTE; PATIENTS OLDER; RITUXIMAB ERA; TRIAL; CHEMOTHERAPY; SURVIVAL; SUBTYPE; MARKER; IPI
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 8/4/2015 11:46.
Abstract
Background: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic Index (IPI) and other significant variables in elderly population treated in the R-CHOP regime has not been carried out yet. Methodology/Principal Findings: In this retrospective study, a cohort of 443 newly diagnosed DLBCL patients with age >= 60 was analyzed. All patients were treated with the R-CHOP therapy. An extensive statistical analysis was performed to identify risk factors of 3-year overall survival (OS). In multivariate analysis, only three predictors proved significant: Eastern Cooperative Oncology Group performance status (ECOG), age and bulky disease presence. These predictors were dichotomized (ECOG >= 1, age >= 70, bulk >= 7.5) to create a novel four-level score. This score predicted 3-year OS of 94.0%, 77.4%, 62.7% and 35.4% in the low-, low-intermediate, high-intermediate and high-risk groups, respectively (P<0.001). Further, a three-level score was tested which stratifies the population better (3-year OS: 91.9%, 67.2%, 36.2% in the low, intermediate and high-risk groups, respectively) but is more difficult to interpret. Both the 3- and 4-level scores were compared to standard scoring systems and, in our population, were shown to be superior in terms of patients risk stratification with respect to 3-year OS prediction. The results were successfully validated on an independent cohort of 162 patients of similar group characteristics. Conclusions: The prognostic role of baseline ALC, AMC or their ratio (LMR) was not confirmed in the multivariate context in elderly population with DLBCL treated with R-CHOP. The newly proposed age-specific index stratifies the elderly population into risk groups more precisely than the conventional IPI and its existing variants.
PrintDisplayed: 27/6/2024 20:57